BNP Paribas Asset Management
PTGX icon

BNP Paribas Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

BNP Paribas Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9M Sell
259,972
-46,065
-15% -$4.81M 0.03% 462
2026
Q1 		$32.3M Sell
306,037
-24,767
-7% -$2.19M 0.04% 437
2025
Q4 		$28.9M Sell
330,804
-120,962
-27% -$9.9M 0.03% 453
2025
Q3 		$30M Buy
451,766
+5,740
+1% +$326K 0.08% 260
2025
Q2 		$24.7M Buy
446,026
+66,377
+17% +$3.19M 0.06% 308
2025
Q1 		$18.4M Buy
379,649
+253,751
+202% +$10.6M 0.05% 358
2024
Q4 		$4.86M Hold
125,898
– – 0.01% 565
2024
Q3 		$5.67M Buy
+125,898
New +$5.09M 0.01% 520

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BNP Paribas Asset Management's PTGX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 15% in Q2 2026, selling an estimated $4.81M and leaving 259,972 shares worth $31.9M. The position accounts for 0.03% of the portfolio, ranked #462.

BNP Paribas Asset Management first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $32.3M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • BNP Paribas Asset Management held 259,972 shares of Protagonist Therapeutics worth $31.9M as of Q2 2026.
  • BNP Paribas Asset Management sold 46,065 Protagonist Therapeutics shares in Q2 2026, an estimated $4.81M.
  • Protagonist Therapeutics made up 0.03% of BNP Paribas Asset Management's portfolio in Q2 2026, its #462 holding.
  • BNP Paribas Asset Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • BNP Paribas Asset Management's Protagonist Therapeutics position peaked at $32.3M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.